Introduction
Prescription drug abuse is defined as using prescription drugs for nonmedical/nonprescribed purposes, such as intoxication or mood alteration. This illegal and dangerous health behavior has increased over the past two decades. Overdose deaths due to prescription painkillers quadrupled from 1999 to 2010, going from 4030 to 16,651, and were more prevalent than overdose deaths from heroin and cocaine combined in 2010 (National Vital Statistics System, 2012) . As of 2010, 60% of all drug overdose deaths were from prescription drugs, with opioids being involved in 3 of every 4 of these deaths. Prescription drug abuse in the United States is now described by the Centers for Disease Control and Prevention (CDC) as an epidemic (National Vital Statistics System, 2012) . The significant increase in prescription drug abuse can largely be attributed to the increased availability of prescription drugs. Although these prescription medications are prescribed for legitimate medical purposes, a portion of them become subject to drug diversion for recreational, non-medicinal use. Increased prescribing and the availability of these drugs are directly correlated to increased overdose deaths (Vital Signs, 2011) . This paper describes an intervention to address this critical public health issue.
The CDC's Injury Center has made combating prescription drug abuse a principal focus of its strategic plan. Among other proposed interventions, they recommend the implementation of state run Prescription Drug Monitoring Programs (PDMP) to help mitigate this public health epidemic (Vital Signs, 2011) . Through utilization of electronic databases, these programs allow enrollees the ability to track where and when patients are acquiring controlled substance (CS) medications, thereby assisting health care professionals in identifying drug seeking patients who may be abusing prescription drugs. PDMPs have the potential to drastically decrease the amount of drug diversion in the United States, which in turn can directly affect the rates of prescription drug abuse and overdose. The AR PMP collects, stores, and monitors the dispensing of CS in Schedules II, III, IV, and V, as well as other state-controlled drugs (Arkansas Department of Health, 2013). Dispensers report patient name, address and date of birth, physician identification, pharmacy identification, prescription number, drug name, strength, quantity and date prescribed. Collection of this data began on March 1, 2013 and must be reported by prescription drug dispensers to the ADH on a weekly basis. Through authorized access to the AR PMP database, practitioners may view the CS dispensing history of their patients, including the exact quantity of medication prescribed by each prescriber and dispensed at each pharmacy, in order to make more informed prescribing and dispensing decisions.
Our objective in this study was to better understand the utilization and performance of the AR PMP during the first year of its implementation. Specifically, we sought to describe (1) the makeup of AR PMP users; (2) the utilization of the AR PMP; and (3) the performance of the program in regard to changing prescribing and dispensing practices. The results of the study survey were used to evaluate how access to the AR PMP is changing health care practices in efforts to address the public health epidemic of prescription drug abuse.
Methods

Procedure
A web survey was developed and administered via SurveyMonkey (online web based survey tool). All enrolled Arkansas prescribers and dispensers (n = 3694) were invited by email to participate in the study survey, which was available for 30 days from February 4 to March 5, 2014. Two reminder emails with the survey link invitation were sent out on days 14 and 28. The survey was designed with seven questions to take no more than 2 min to complete at the individual's convenience over the course of 30 days. The survey was anonymous and e-mail addresses were deleted at the end of the survey period. The ADH reviewed and determined that the survey project did not require human subject review.
Measures
Survey questions were designed by investigators of the study after review of other states' PDMP surveys and upon solicitation of AR PMP staff suggestions and statistical expert opinions. All survey questions were closed-ended (Appendix A). The AR PMP User Survey was created with three objectives. The first study objective, to describe the makeup of AR PMP users, was addressed by the following: "Which of the following best describes your profession?" and "Where is your primary practice located?" The second study objective, to identify the utilization of the AR PMP, was answered by the following: "How often do you use the AR PMP?", "When do you use the AR PMP?" and "What prompts you to access the AR PMP?" The last study objective, to identify how the AR PMP has changed prescribing and dispensing practices, was answered by the last two survey questions in order to determine the performance of the program over the past year. One question was more patient specific: "After reviewing the AR PMP, how has a patient encounter been altered?" and the other more practice specific: "How has access to the AR PMP changed your prescribing/dispensing practices?" All statistical data analyses for this study were generated using SAS® software, Version 9.3 of the SAS System for Windows. 
Results
User makeup and program utilization
The makeup of the AR PMP User Survey participants is outlined in Table 1 , closely resembling the actual AR PMP user composition that was calculated in March 2014 by the ADH (Arkansas Department of Health, 2013). There were a total of 1541 individuals who completed the survey, giving an overall response rate of 41.7%. Survey respondents were from health care practices located in all 75 Arkansas counties. The utilization of the AR PMP is described in terms of frequency of access, timing of access, and reasons for access of the AR PMP, as outlined in Table 1 .
Very few (4%) AR PMP enrollees reported never accessing the program. Of those who access the AR PMP daily, 43% are PharmD/PDs, 36% are MDs, and 14% are APNs. Similar to the frequency of access distribution of all AR PMP users as outlined in Table 1 , the frequency of use by MDs, APNs and PharmD/PDs is equally distributed in terms of how often they access the program.
Among the daily and infrequent users (those who use the program less than three times a month), the most common reasons to access the program are similar: suspicion of drug misuse or drug diversion (92% of infrequent users and 84% of daily users, Chi-square statistical test p-value = 0.0024) and requests from other prescribers or pharmacists (29% of infrequent users and 28% of daily users, p-value = 0.8156). However, daily users are considerably more likely than infrequent users to be prompted to access the program simply due to any involvement of a CS prescription (49% v. 8%, p-value b 0.0001), any involvement of a C-II CS prescription (32% v. 5%, p-value b 0.0001) or requirements per office or facility policy (22% v. 4%, p-value b 0.0001). Fig. 1 shows the reasons that AR PMP users are prompted to access the program among the professions with the most frequent use of the program.
Changes in health care practices
Among the 1475 study participants who access the AR PMP, the most common response as to how access to the program has impacted their health care practices was by causing a decrease in the number of CS prescriptions issued or dispensed (61%), closely followed by causing them to provide more patient education and/or counseling on CS prescription use and abuse (57%). Access to the AR PMP is also causing users to decrease the quantity of dosage units prescribed (24%) and to increase the number of prescriptions changed from a C-II to a C-III/C-IV (7%). An insignificant number of survey respondents (0.8%) reported an increased number of CS prescriptions issued or dispensed after access to the AR PMP.
Compared to infrequent users who utilize the program less than three times a month, those who access the program daily were almost twice as likely to report that the program has caused them to decrease the number of CS prescriptions issued or dispensed (76% v. 39%, pvalue b 0.0001). Daily users were 23% more likely to report that the AR PMP has caused them to provide more patient education and/or counseling on CS prescription use and abuse (67% v. 44%, pvalue b 0.0001), they were twice as likely to report the AR PMP has caused them to decrease the quantity of dosage units prescribed for CS prescriptions (30% v. 15%, p-value b 0.0001) and they were almost three times as likely to report the AR PMP has caused an increase in prescriptions changed from a C-II to a C-III/C-IV (11% v. 4%, p-value = 0.0006) after accessing the AR PMP.
Reported changes to health care practice after accessing the AR PMP by the professions with the most frequent use of the program are shown in Fig. 2 .
Discussion
The epidemic of prescription drug abuse has resulted in calls for new measures to address this devastating, life threatening public health issue. The AR PMP, as authorized by Arkansas Act 304 of 2011, has already changed health care practices across the state during its first year of operation. The results of this study show that the makeup of AR PMP users can be described as prescribing and dispensing health care professionals representing all 75 Arkansas counties. Program utilization analysis showed a large portion of AR PMP users regularly access the program either two to three times weekly or daily, with the majority of users accessing before issuing or dispensing a CS prescription, potentially preventing CS medications from being obtained by drug seekers or In the survey, respondents could choose all reasons that apply to them, 31 medical doctors, 7 advanced practice nurses and 22 pharmacists who answered "never" to the frequency of access question were excluded, CS: controlled substance, rx: medical prescription. being misused and abused. Performance analysis showed that access to the AR PMP relates to changes in health care practices. A majority of AR PMP users responded that the program had caused them to decrease the number of CS prescriptions issued or dispensed and to provide more patient education and/or counseling on CS medication use and abuse. Program use also resulted in decreases in the dosage unit quantity of CS medication issued or dispensed and increases in the number of prescriptions changed from a C-II to a C-III/C-IV medication. These are positive actions in achieving the goals set out by the AR PMP. During the first year of implementation, the program demonstrated potential to mitigate misuse and abuse of CS medications. Through access to the AR PMP, health care professionals are better able to ensure the legitimate use of CS prescriptions and to take necessary measures when diversion is suspected.
This study demonstrated several limitations beginning with the low response rate of 41.7%. This response rate is likely attributable to several factors; email filter blocking of SurveyMonkey emails, the decision not to include partially completed surveys (3% of respondents) in the analyses, and the relatively short window for response (30 days).
Additionally it is possible that non-respondents were not able to access the AR PMP as often as respondents resulting in a possible overestimate of AR PMP utilization rates.
While the seven question survey instrument was intentionally brief in order to encourage participation from busy health care professionals, a longer survey could provide more refined information regarding AR PMP users and its impact on their prescribing practices.
Questions 4 through 7 of the survey allowed participants to choose the response N/A. This response option may have been selected for several reasons, including that they never use the program, they found none of the responses satisfactory, or they had additional responses they wished to express. This option resulted in a level of impreciseness in the study results.
Also, it is possible that changes in health care practices related to CS prescribing and dispensing could also be attributed to unknown forces operating concurrently to the operation of the AR PMP, confounding the results of this study.
Finally, the results of this study came from a PDMP operating in Arkansas, a largely rural state. Extrapolating from these results to more urbanized states should be undertaken with care.
Conclusion
It appears clear that the AR PMP has positively impacted prescription drug abuse in our state. Increased frequency of access by health care providers to the PDMP appears essential to improving their CS practices. Daily users are significantly more likely than infrequent users to be prompted to access the AR PMP simply by the involvement of a CS prescription or by requirements per office or facility policy. Currently, neither Arkansas law nor regulation mandates that CS prescribers and dispensers access the AR PMP. It is likely that legal and regulatory requirements will result in increased PDMP utilization. Additionally, increased utilization of the AR PMP database is likely to occur as a result of planned program enhancements such as unsolicited reporting (providing alerts to registered and non-registered users of the appearance of misuse or abuse by a patient) and allowing prescribers/dispensers to designate delegates to access the database. These actions along with continued support of stakeholders in the adoption of CS prescribing and dispensing guidelines by healthcare facilities remain key strategies in combating prescription drug abuse. . a In the survey, respondents could choose all reasons that apply to them; 31 medical doctors, 7 advanced practice nurses and 22 pharmacists who answered "Never" to the frequency of access question were excluded, CS: controlled substance, rx: medical prescription. Since a PharmD/PD cannot prescribe medications in Arkansas, the prescriber would have had to be contacted, therefore prompting a prescription change.
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